This 173-page report, “Global Pharmaceutical Contract Manufacturing Market 2020-2030 by Category, Product (API, FDF), Phase (Clinical, Commercial), Type (Sterile, Non-Sterile), Therapeutic Application, and Region: Trend Forecast and Growth Opportunity,” is highlighted by 87 tables and 85 figures and is based on extensive research of the entire global pharmaceutical contract manufacturing market and all of its sub-segments. Premium primary and secondary information sources are used to create in-depth research and evaluation, with input coming from business specialists working throughout the value chain.
The market for pharmaceutical contract manufacturing will reach $184.8 billion by 2030, expanding at a 6.2% annual rate from 2020 to 2030, driven by a rising reliance on these companies due to increased productivity and efficiency in the face of the COVID-19 pandemic.
The research uses 2019 as the foundation year for its estimate, which ranges from 2020 to 2030 and is based on studies from 2015 to 2019. (Please note that the report will be updated before to delivery to ensure that the forecast includes at least 5 years beyond the base year and the most recent historical year serves as the base year.)
Request Research Sample with Latest Industry Insights: https://altusmarketresearch.com/reports/sample/3468
The following elements are identified and examined in-depth qualitative analyses:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
By taking COVID-19 into consideration, the trend and prognosis for the global market are predicted with an upbeat, fair-minded, and cautious viewpoint. The worldwide pharmaceutical contract manufacturing market is quantified from the standpoints of Category, Product, Phase, Type, Therapeutic Application, and Region using the balanced (most likely) forecast.
The worldwide market is divided into the following sub-markets according to category, with annual revenue for 2019–2030 mentioned in each area.
• Pharmaceutical Industry
• Biopharmaceutical Industry
Based on Product, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Active Pharmaceutical Ingredients (API)
• Branded API Manufacturing
• Generic API Manufacturing
Finished Dosage Formulations (FDF)
• Solid Dosage
• Oral Liquids
• Parenteral/Injectables
• Other FDFs
Secondary Packaging
Based on Phase, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Clinical Manufacturing
• Commercial Manufacturing
Based on Type, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Sterile Products
• Non-Sterile Products
Based on Therapeutic Application, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Infectious Diseases
• Oncology
• Metabolic Disorders
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Gastrointestinal Disorders
• Other Therapeutic Applications
Along with the above national/local markets, the following geographic areas are thoroughly investigated:
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
In Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
• America, North (U.S., Canada, and Mexico)
Latin America (Brazil, Chile, Argentina, Rest of South America)
• MEA (Saudi Arabia, UAE, South Africa)
There are thorough analyses and statistics for yearly revenue for each of the aforementioned regions and nations for the years 2019 through 2030. All regional markets are broken down by country, and major national markets are divided according to product, phase, and therapeutic use during the predicted years.
The study also analyses the present competition landscape, the anticipated trend, and it provides profiles of major suppliers, including both established market leaders and significant up-and-coming companies.
Through AMR’s Risk Assessment System, possible risks related to investing in the worldwide pharmaceutical contract manufacturing business are evaluated quantitatively and qualitatively. Critical Success Factors (CSFs) are developed based on the risk analysis and assessment as a guide to assist investors and shareholders in identifying new possibilities, managing and minimising risks, developing suitable business models, and making informed strategies and choices.
Key Players (this list may not be exhaustive; other businesses may be included upon request):
Aenova Group
Baxter BioPharma Solutions
Boehringer Ingelheim
Catalent Inc.
Famar S.A.
Hospira, Inc.
Jubilant Life Sciences Ltd.
Lonza Group
Patheon Inc.
Pfizer CentreSource
Recipharm AB
Vetter Pharma International GmbH